Guixing Li

Prof. Guixing Li


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HHHua-Lan Huang
Hua-Lan Huang
XNXin Nie
Xin Nie
BCBei Cai
Bei Cai
JTJiang-Tao Tang
Jiang-Tao Tang
YHYong He
Yong He
GLGuixing Li
Guixing Li
Acute kidney injury (AKI) has been proposed as a leading cause of mortality for acute pancreatitis (AP) patients admitted to the intensive care unit (ICU). This study investigated the predictive value of procalcitonin (PCT) for AKI development and relevant prognosis in patients with AP, and compared PCT’s predictive power with that of other inflammation-related variables. Between January 2011 and March 2013, we enrolled 305 cases with acute pancreatitis admitted to ICU. Serum levels of PCT, serum amyloid A (SAA), interleukin-6 (IL-6), and C reactive protein (CRP) were determined on admission. Serum PCT was tested in patients who developed AKI on the day of AKI occurrence and on either day 28 after occurrence (for survivors) or on the day of death (for those who died within 28 days). Serum PCT levels were 100-fold higher in the AKI group than in the non-AKI group on the day of ICU admission (p<0.05). The area under the receiver-operating characteristic (ROC) curve of PCT for predicting AKI was 0.986, which was superior to SAA, CRP, and IL-6 (p<0.05). ROC analysis revealed all variables tested had lower predictive performance for AKI prognosis. The average serum PCT level on day 28 (2.67 (0.89, 7.99) ng/ml) was significantly (p<0.0001) lower than on the day of AKI occurrence (43.71 (19.24,65.69) ng/ml) in survivors, but the serum PCT level on death (63.73 (34.22,94.30) ng/ml) was higher than on the day of AKI occurrence (37.55 (18.70,74.12) ng/ml) in non-survivors, although there was no significant difference between the two days in the latter group (p = 0.1365). Serum PCT is superior to CRP, IL-6, and SAA for predicting the development of AKI in patients with AP, and also can be used for dynamic evaluation of AKI prognosis.

18 March 2013 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PDF file
XNXin Nie
Xin Nie
BWBin Wu
Bin Wu
YHYong He
Yong He
XHXunbei Huang
Xunbei Huang
ZDZhongqiu Dai
Zhongqiu Dai
GLGuixing Li
Guixing Li
Background:Procalcitonin (PCT) is an early, sensitive, and accurate marker for diagnosing infection and sepsis. As sepsis and septic shock are dominant causes of acute kidney injury (AKI), we investigated whether PCT is an early predictor of AKI in patients with symptoms of infection.Methods:Between January 2011 and October 2011, 1361 inpatients in West China Hospital who displayed infection symptoms were enrolled in our study. Levels of PCT, serum amyloid A (SAA), C-reactive protein (CRP), interleukin-6 (IL-6), and white blood cell count (WBC) were determined and participants’ renal function was monitored for 3 consecutive days.Results:The rate of AKI occurrence 3 days after enrollment was 14.6%. Higher PCT levels were correlated with higher AKI occurrence rates and higher levels of serum urea, creatinine, and cystatin C (p<0.05). The area under the receiver-operating characteristic (ROC) curve (AUC) for PCT was 0.823, making it more predictive (p<0.0001) than SAA, CRP, IL-6, or WBC. The cut-off value of 1.575 ng/mL for PCT had the highest validity for predicting AKI in patients with infection symptoms. The sensitivity, specificity, negative-predictive value (NPV), positive-predictive value (PPV), negative-likelihood ratio (LR-), and positive-likelihood ratio (LR+) for this cut-off value were 61.7%, 84.6%, 93.6%, 37.5%, 0.415, and 4.98, respectively.Conclusions:PCT can be used as a predictive marker for sepsis-induced acute kidney injury in patients with symptoms of infection.

1 April 2021 in Clinical Biochemistry
Verified
Journal Article
Closed access
FDFei Ding
Fei Ding
XNXin Nie
Xin Nie
XLXiaoling Li
Xiaoling Li
YHYong He
Yong He
GLGuixing Li
Guixing Li

1 January 2015 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
HHHualan Huang
Hualan Huang
SZShuai Zhu
Shuai Zhu
WWWeiqing Wang
Weiqing Wang
HYHong Yi
Hong Yi
XDXiangyang Du
Xiangyang Du
GLGuixing Li
Guixing Li
Background: The objective of this study was to examine the diagnostic accuracy of high-sensitivity cardiac troponin T (hs-cTnT) for acute myocardial infarction (AMI) in patients with renal insufficiency, since this population has a high incidence of non-AMI elevations of hs-cTnT. Methods: In this prospective study, we enrolled 2249 consecutive patients presenting with chest pain in the emergency department (ED), of whom 19.5% had an estimated glomerular filtration rate (eGFR)cys of <60 mL·min–1 (1.73 m2)–1. Hs-cTnT levels were measured blindly at presentation. Results: Of the patients, 1108 (49.3%) were diagnosed as having AMI [321 with non-ST segment elevation myocardial infarction (NSTEMI)]. In patients whose final diagnosis was not AMI, there was a low but significant correlation between hs-cTnT and renal function [eGFRcys, r=–0.43 (–0.48, –0.38), p<0.001; eGFRcreat, r=–0.33 (–0.38, –0.27), p<0.001]. The area under the curve of the receiver operating characteristic (AUC) for hs-cTnT to diagnose AMI was 0.93 in patients with eGFRcys levels of <30 mL·min–1 (1.73 m2)–1, and AUCs did not vary significantly according to eGFR categories. On the basis of the ROC curve, the optimal threshold value for hs-cTnT was 143.6 ng·L–1 to diagnose AMI in patients with eGFRcys of <30 mL·min–1 (1.73 m2)–1, with a sensitivity of 83% and a specificity of 91%; 54.1 ng·L–1 in patients with eGFRcys between 30 and 59 mL·min–1, with a sensitivity of 90% and a specificity of 87%; 30.0 ng·L–1 in patients with eGFRcys between 60 and 89 mL·min–1, with a sensitivity of 89% and a specificity of 85%; and 20.3 ng·L–1 in patients with eGFRcys ≥90 mL·min–1 (1.73 m2)–1, with a sensitivity of 92% and a specificity of 88%. The same observations were done for the diagnosis of NSTEMI. Conclusions: Using a higher hs-cTnT cut-off value based on eGFR level is necessary for accurate diagnosis of AMI or NSTEMI in patients with renal insufficiency.

15 December 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
QLQianhui Liu
Qianhui Liu
MYMengting Yin
Mengting Yin
GLGuixing Li
Guixing Li
Objective: Antithyroglobulin antibody (TgAb) is a potential tumour marker for detecting differentiated thyroid cancer (DTC) recurrence, but insufficient data have supported its clinical applications. Our study aimed to describe the changing trend of TgAb after surgery and identify the relationship between this trend and clinical outcomes.Patients and Methods: We reviewed the electronic records of 1,686 DTC patients who had undergone total thyroidectomy (TT) and radioactive iodine (131I) therapy at West China Hospital of Sichuan University from January 2015 to December 2017. Finally, 289 preoperative TgAb-positive DTC patients were included and divided into four subgroups depending on the clinical outcome: Group A (tumour free), Group B (uncertain), Group C (incomplete biochemical response), and Group D (structural disease). The patient demographics, tumour characteristics, operations, pathology reports, and all serological biomarkers were reviewed and compared, and the prognostic efficacy of TgAb was evaluated.Results: Among all 1,686 patients, 393 (23.65%) were TgAb positive (>40 IU/ml) preoperatively. The TgAb level in Group A decreased significantly after surgery and 131I therapy and stabilised at a low level after 1–2 years of 131I therapy. However, in the other three groups, the decrease in TgAb was not significant after treatment. Conversely, TgAb declined slowly and remained stable or increased. The variations in TgAb relative to the preoperative level of Group A were significantly larger than those of Groups B, C, and D at most time points of follow-up (p < 0.001). By receiver operating characteristic (ROC) analyses, the variations of TgAb > −77.9% at 6 months after 131I therapy (area under the curve (AUC) = 0.862; p < 0.001) and TgAb > −88.6% at 2 years after 131I therapy (AUC = 0.901; p < 0.001) had good prognostic efficacy in tumour-free survival. When the variation in TgAb > −88.6% at 2 years after 131I therapy was incorporated as a variable in the American Thyroid Association (ATA) categories, both intermediate- and high-risk patients also had a significantly increased chance of being tumour free (from 75.68% to 93.88% and 42.0% to 82.61%, respectively).Conclusions: For preoperative TgAb-positive DTC patients, variations in TgAb > −77.9% at 6 months after 131I therapy and TgAb > −88.6% at 2 years after 131I therapy had good prognostic efficacy. Their incorporation as variables in the ATA risk stratification system could more accurately predict disease-free survival.

12 August 2018 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Closed access
PDF file
WLWei Luo
Wei Luo
YHYong He
Yong He
FDFei Ding
Fei Ding
XNXin Nie
Xin Nie
XLXiao‐Ling Li
Xiao‐Ling Li
GLGuixing Li
Guixing Li